[HTML][HTML] Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations
GT Ferguson, A Anzueto, R Fei, A Emmett, K Knobil… - Respiratory …, 2008 - Elsevier
OBJECTIVES: COPD exacerbations are associated with significant morbidity and mortality.
This randomized, double-blind, parallel-group, multicenter study evaluated the effect of …
This randomized, double-blind, parallel-group, multicenter study evaluated the effect of …
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes
A Anzueto, GT Ferguson, G Feldman… - COPD: Journal of …, 2009 - Taylor & Francis
Prevention and treatment of COPD exacerbations are recognized as key goals in disease
management. This randomized, double-blind, parallel-group, multicenter study evaluated …
management. This randomized, double-blind, parallel-group, multicenter study evaluated …
[HTML][HTML] Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study
A Sharafkhaneh, JG Southard, M Goldman… - Respiratory …, 2012 - Elsevier
BACKGROUND: Treatment with an inhaled corticosteroid (ICS) and long-acting
bronchodilator is recommended for severe/very severe chronic obstructive pulmonary …
bronchodilator is recommended for severe/very severe chronic obstructive pulmonary …
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a …
EFM Wouters, DS Postma, B Fokkens, WCJ Hop… - Thorax, 2005 - thorax.bmj.com
Background: Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment
for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator …
for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator …
Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations
PW Jones, LR Willits, PS Burge… - European Respiratory …, 2003 - Eur Respiratory Soc
Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with worse
health and increased healthcare utilisation. The Inhaled Steroids in Obstructive Lung …
health and increased healthcare utilisation. The Inhaled Steroids in Obstructive Lung …
[HTML][HTML] Effectiveness of fluticasone furoate–vilanterol for COPD in clinical practice
J Vestbo, D Leather, N Diar Bakerly… - … England Journal of …, 2016 - Mass Medical Soc
Background Evidence for the management of chronic obstructive pulmonary disease
(COPD) comes from closely monitored efficacy trials involving groups of patients who were …
(COPD) comes from closely monitored efficacy trials involving groups of patients who were …
Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis
J Wang, B Nie, W Xiong, Y Xu - Journal of clinical pharmacy …, 2012 - Wiley Online Library
Summary What is Known and Objective: Inhaled long‐acting beta‐agonists have been
licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late …
licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late …
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease
P Kardos, M Wencker, T Glaab… - American journal of …, 2007 - atsjournals.org
Rationale: Exacerbations of chronic obstructive pulmonary disease (COPD) greatly
contribute to declining health status and the progression of the disease, thereby incurring …
contribute to declining health status and the progression of the disease, thereby incurring …
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group …
MT Dransfield, J Bourbeau, PW Jones… - The Lancet …, 2013 - thelancet.com
Background Whether the combination of a once-daily inhaled corticosteroid with a once-
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …
Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS …
K Larsson, C Janson, K Lisspers… - Journal of internal …, 2013 - Wiley Online Library
Objectives Combinations of inhaled corticosteroids (ICS s) and long‐acting β2‐agonists
(LABA s) are recommended for patients with moderate and severe chronic obstructive …
(LABA s) are recommended for patients with moderate and severe chronic obstructive …
相关搜索
- fluticasone propionate patients with copd
- fluticasone furoate exacerbations of copd
- fluticasone propionate disease exacerbations
- copd exacerbations patient outcomes
- fluticasone salmeterol budesonide formoterol
- copd exacerbations beta agonists
- copd exacerbations meta analysis
- fluticasone furoate prevention of exacerbations
- fluticasone propionate disease deterioration
- fluticasone propionate disease severity